![Robert E. Ivy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Robert E.
Ivy was appointed a Director of Sonus Pharmaceuticals, Inc. in February 1999 and Chairman in December 2005 and is Chairman of the Nominating and Governance Committee and a Member of the Audit Committee.
He has been President of INSIGHT, Inc. since October 1999.
Mr. Ivy had served as Co-Chairman of Sonus Pharmaceuticals since July 1999.
From 1987 to 1999, he was Chairman, President and Chief Executive Officer of Ribi ImmunoChem.
Previously, Mr. Ivy was President, Chief Executive Officer and a Director of OSI Pharmaceuticals, Inc. and Berlex Laboratories, Inc. and President for the U.S.V.
Pharmaceutical Division of Revlon Health Care Group.
He began his career with G.D.
Searle & Co. in sales and marketing rising to the position of Vice President of Marketing and Sales.
Mr. Ivy received a BS degree in Chemistry and Biology from Northwestern University and attended the Northwestern University Medical School.
Ehemalige bekannte Positionen von Robert E. Ivy
Unternehmen | Position | Ende |
---|---|---|
Sonus Pharmaceuticals, Inc.
![]() Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Vorsitzender | 22.08.2008 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Sonus Pharmaceuticals, Inc.
![]() Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |